Gina Columbus

Emily M. Ko, MD, discusses the implications of two clinical trial findings for patients with endometrial cancer, and how several risk factors may lead to a surgical treatment delay.

John L. Marshall, MD, discusses second-line treatment options for patients with metastatic colorectal cancer, along with who is most appropriate to receive regorafenib (Stivarga) and how to manage doses and toxicities when using the multikinase inhibitor.

Approximately 46% of patients with breast cancer at high risk for recurrence but low genomic risk with the 70-gene breast cancer recurrence assay (MammaPrint) might not require adjuvant chemotherapy.

Richard Levine, MD, discusses the selection of therapies available for patients with metastatic castration-resistant prostate cancer and the next steps in the field.

Kosj Yamoah, MD, discusses health disparities in prostate cancer and unanswered questions researchers still need to tackle.

Julio Pow-Sang, MD, discusses the significance of assessing risk status, options for patients with prostate cancer whose risk status falls in a "grey-zone," and how technology is helping oncologists more accurately characterize risk.

Jingsong Zhang, MD, PhD, discusses his vision for treating patients with metastatic castration-resistant prostate cancer.

Michael Poch, MD, provides deeper insight into how immunotherapy has propelled the field of bladder cancer forward, as well as the research that still needs to be done.

Mayer Fishman, MD, discusses the therapeutic landscape in renal cell carcinoma and the next steps needed to further advance the field.

Conor Lynch, PhD, sheds light on the biology of bone metastases as well as the mechanism of action for bone-directed therapies for patients with metastatic castration-resistant prostate cancer.

Heather Jim, MD, describes the psychological impacts of testosterone-lowering drugs for patients with prostate cancer—and what oncologists should do to help.

Peter Johnstone, MD, provides insight on post-prostatectomy radiation therapy for patients with prostate cancer.

Russell Szmulewitz, MD, discusses the unknown optimal use of radium-223 dichloride (Xofigo), the appropriate time to administer it, and the associated challenges with the agent for the treatment of patients with metastatic castration-resistant prostate cancer.

A 2-mm margin should be the standard for patients with ductal carcinoma in situ undergoing breast conserving surgery with whole breast irradiation.

Paul A. Bunn Jr, MD, discusses the meaning of the CheckMate-026 results with frontline nivolumab in NSCLC and issues with the trial's primary endpoint of progression-free survival.

Gary D. Steinberg, MD, discusses the impact of atezolizumab (Tecentriq) on the treatment landscape of bladder cancer, the resistance to finding effective therapies for the disease, and what potential role immunotherapy may have in the field going forward.

Randy F. Sweis, MD, covers the immunotherapy advancements in prostate cancer, renal cell carcinoma, and bladder cancer, and what refinement lies ahead in each of these areas.

New classes of immunotherapies emerging in lung cancer are building on previous success with PD-1/PD-L1 inhibitors.

Gregory Zagaja, MD, discusses the benefits of radical prostatectomy and other ongoing developments with surgery in prostate cancer.

Russell Szmulewitz, MD, discusses optimal treatment strategies for patients with metastatic castration-resistant prostate cancer and highlights emerging therapies in the therapeutic landscape.

Vamsidhar Velcheti, MD, discusses recent advancements in the ALK-positive landscape of non-small cell lung cancer, along with key questions that still remain.

James Stevenson, MD, discusses developments and ongoing research in squamous non-small cell lung cancer.

Stanley Liauw, MD, discusses the evolving role of radiation therapy in locally advanced prostate cancer and how it compares with surgical options.

Kevin Stephans, MD, discusses the latest research developments in oligometastases for patients with lung cancer.

Daniel P. Petrylak, MD, professor of Medicine, Yale Cancer Center, discusses his vision for radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer and how it integrates with chemotherapy and other agents for treatment of this patient population.

Robert Dreicer, MD, discusses the key questions that surround the optimal use and sequencing of radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer and how the treatment has altered the field of radiopharmaceuticals.

Nathan Pennell, MD, PhD, discusses 3 available—and competing—agents in EGFR-mutant non–small cell lung cancer, as well as ongoing clinical trials at Cleveland Clinic exploring other regimens for this patient population.

Scott Eggener, MD, discusses the implications of the Prostate, Lung, Colorectal, and Ovary trial update, and shares his views on PSA-based screening and how to appropriately use it for patients with early-stage prostate cancer.

Mark W. Kris, MD, discusses immunotherapy, frontline therapies for nonsquamous non–small cell lung cancer, and advancements in squamous cell carcinoma.

Brentuximab vedotin showed a 5-year overall survival rate of 41% for patients with relapsed or refractory classical Hodgkin lymphoma, suggesting a cure for some patients.